Kato T.,Aichi Koseiren Toyotakousei Hospital |
Inagaki K.,Aichi Koseiren Toyotakousei Hospital |
Sawai Y.,Aichi Koseiren Toyotakousei Hospital |
Kanayama H.,Aichi Koseiren Toyotakousei Hospital |
And 2 more authors.
Experimental and Clinical Endocrinology and Diabetes | Year: 2011
The present study was undertaken to compare the efficacy of pitavastatin and colestimide in patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome. 48 diabetic patients with metabolic syndrome were randomly assigned to a pitavastatin group or colestimide group. The clinical parameters, serum lipids, fasting (FPG) and postprandial plasma glucose(PPG), HOMA-IR, hemoglobin A1c(HbA1c), hs-CRP and urinary albumin were measured before/after 24-week administration. Treatment with pitavastatin reduced LDL-C and TG, while that with colestimide significantly reduced waist circumference, BMI, LDL-C, HbA1c, FPG, PPG, HOMA-R, hs-CRP and urinary albumin. Percent improvement in LDL-C was greater in the pitavastatin group than in the colestimide group. Colestimide appeared to be useful in the management of Japanese patients with diabetes mellitus complicated by metabolic syndrome, since it alleviates obesity and insulin resistance in addition to exhibiting lipid profile-improving effects, and can thus improve markers of atherosclerosis. © 2011 J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart. New York. Source